Windlas Biotech Ltd.
900.40
INR
+19.10
(+2.17%)
Windlas Biotech Ltd.
NSE:WINDLAS
(National Stock Exchange of India)
Recent
price
900.40
P/E
ratio
27.17
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Windlas Biotech Limited Windlas Biotech Limited engages primarily as a pharmaceutical contract development and manufacturing organization (CDMO) in India, producing solid and liquid dosage forms including tablets, capsules, syrups, and injectables; it provides end-to-end CDMO services encompassing product discovery, formulation development, licensing, commercial manufacturing of complex generics, and handling of high-potency drugs, controlled substances, narcotics, and low-solubility compounds across therapeutic areas such as anti-diabetic, cardiovascular, neuropsychiatry, respiratory, gastroenterology, dermatological, analgesics, anti-infectives, urology, nutritional supplements, vitamins/minerals/supplements, and veterinary products. The company sells branded formulations in domestic trade generics and over-the-counter markets focused on pain management, gastro management, nutritional food/supplements, derma/hair care, antibiotics, diabetic/cardiac management, neuro/psychiatry, thyro care, ENT/eye/oral care, and women's health; it also exports generic products to 19 countries including semi-regulated and selective regulated markets in regions of Africa, Asia, Latin America, and the rest of the world. Founded in 2001 and headquartered in Dehradun, Uttarakhand, with a corporate office in Gurugram, Haryana, Windlas Biotech Limited operates three strategic business verticals—CDMO services/products, domestic trade generics/OTC brands, and exports—serving over 100 pharmaceutical companies including 7 of the top 10 and 15 of the top 20 Indian formulators. Recent developments include the successful completion of a Rs 25 crore share buyback in Q1 FY24, approval and amalgamation of Windlas Healthcare, capital expenditures of INR 79.18 crores in FY23 followed by INR 15.2 crores and INR 12 crores for fixed assets and specialized equipment, upgrade and capacity expansion of the recently acquired Plant 6, enhancement of its injectable facility for ampoules, vials, and lyophilized products to enter the injectables segment, and sustained revenue growth with Q1 FY26 operations at Rs 210.1 crore (up 19.9% YoY) and September 2025 consolidated net sales at Rs 222.40 crore alongside EPS improvement to Rs 8.48.